An investigation demonstrates how polymer interactions reduce insulin's bioavailability and effectiveness in diabetes treatment, suggesting new therapeutic considerations.
Insulin, a therapeutic peptide for Type I diabetes, can interact with polymers commonly found in healthcare settings via hydrophobic interactions, potentially triggering agglomeration while reducing its bioavailability and therapeutic efficacy.
No takes yet. Share an insight, caveat, or question.
Fagihi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: